Trial Profile
Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Caffeine (Primary) ; Dextromethorphan (Primary) ; Ixekizumab (Primary) ; Midazolam (Primary) ; Omeprazole (Primary) ; Vitamin K (Primary) ; Warfarin (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 22 Dec 2017 Status changed from active, no longer recruiting to completed.
- 04 Aug 2017 Status changed from recruiting to active, no longer recruiting.